A 55-year-old non-smoking woman was admitted to our hospital for re-evaluation of unimproved peripheral ground-glass opacities despite prednisolone and cyclosporine treatment. She was diagnosed with autoimmune pulmonary alveolar proteinosis (PAP) based on transbronchial lung biopsy and granulocyte/macrophage colony-stimulating factor (GM-CSF) antibody testing. GM-CSF inhalation therapy markedly improved the opacities. Bilateral, centrally located lung opacities are typical in PAP, however 10 PAP cases with peripheral infiltration were reported in Japan recently, of which GM-CSF antibody was positive in six. To avoid inappropriate immunosuppressant treatment, PAP should be considered in the differential diagnosis of such peripheral opacities. GM-CSF antibody might be useful for diagnosis.
Introduction
Pulmonary alveolar proteinosis (PAP), first described in 1958 (1) as a rare and severe lung disease characterized by the intra-alveolar accumulation of surfactant lipids and proteins, impairs gas exchange and results in progressive respiratory insufficiency. Currently, PAP is classifiable into four classes: congenital PAP, autoimmune (idiopathic) PAP, secondary PAP, and unclassified PAP. More than 90% of cases are diagnosed as autoimmune PAP (2) . Patients with autoimmune PAP present high levels of autoantibodies against the granulocyte/macrophage colony-stimulating factor (GM-CSF) in the serum as well as in bronchoalveolar lavage fluid (2) (3) (4) (5) (6) .
Findings from computed tomography (CT) studies of PAP include air space ground-glass interlobular and intralobular opacities and consolidation, which are distributed in a geographic or patchy pattern from the central to peripheral zones (7, 8) . Usually, the distribution of PAP shadows is predominantly central: it is rarely peripheral. Furthermore, previous reports show that the peripheral shadows in PAP patients disappear without treatment (9, 10) . Here, we describe a patient with autoimmune PAP showing peripheral ground-glass appearance that worsened during steroid and cyclosporine therapy, however it was improved with GM-CSF inhalation therapy. 
Case Report
A previously healthy 55-year-old non-smoking woman who had a normal chest radiograph at an annual health check-up 1 year previously was referred to our affiliated hospital because of the appearance of bilateral peripheral shadows on a chest radiograph in September 2004 (Fig. 1A) . The patient was a homemaker without a remarkable family history. She had shortness of breath on exertion (Grade 1 of MRC Breathlessness Scale). A chest CT image revealed subpleural heterogeneous ground-glass opacities (GGOs) partially including consolidation and without definite interlobular thickening ( Fig. 2A) . Examination of the bronchoalveolar lavage fluid (BALF) revealed lymphocytosis (macrophages, 75.5% of total cells; lymphocytes, 23.5%; neutrophils, 1%) with no turbidity, no foamy macrophages, and no amorphous materials. Transbronchial lung biopsy (TBLB) yielded no specific or diagnostically helpful finding. A serum level of KL-6, a mucin-like glycoprotein, was 611 U/mL. Based on these findings, she was provisionally diagnosed with cryptogenic organizing pneumonia. Because the symptom did not improve during the initial observation, she was treated with oral prednisolone (0.5 mg/kg) for three months, but showed no clinical improvement. She was referred to our hospital in December 2004. The patient did not agree to undergo further examination and therefore was treated with prednisolone for 1 year. However, peripheral shadows on the chest radiograph worsened (Fig. 1B) . Later, cyclosporine was added to her treatment for three months. The chest radiograph and CT findings worsened with time ( Fig. 1C, 2B ). She was admitted to our hospital for reevaluation in December 2005.
Laboratory studies showed an elevated white blood cell count (11,600/μL), probably because of steroid therapy (Table 1). Serum levels of total bilirubin were elevated by an unknown cause. Levels of surfactant protein D (SP-D) (151.2 ng/mL) and KL-6 (1,176 U/mL) were increased significantly. Arterial blood gas analysis in room air revealed mild hypoxemia (partial pressure of oxygen (PaO2), 67.6 Torr), indicating a significantly expanded alveolar-arterial oxygen gradient (A-aDO2). Pulmonary function tests indicated normal respiratory functions. Electrocardiography indicated slight sinus tachycardia at 116 beats/min, perhaps associated with hypoxemia. A repeat of bronchoscopy revealed milky lavage fluid containing large foamy macrophages (macrophages, 84%; lymphocytes, 15%; neutrophils, 1%; Fig. 3A ). The TBLB specimens showed that the alveoli with preserved lung architecture were filled with periodic acidSchiff (PAS)-positive eosinophilic amorphous materials (Fig. 4) . The serum was positive for GM-CSF antibody (41.3 μg/mL). Autoimmune PAP was diagnosed based on the detection of GM-CSF antibody in the serum.
Although prednisolone and cyclosporine were discontin- 
Figure 2. Chest computed tomography (CT) revealed peripheral ground-glass opacities (A), which worsened after oral prednisolone and cyclosporine regime (B) and improved markedly after 6-month GM-CSF inhalation therapy (C).
(A) (B) (C) ued, the opacities did not improve during the subsequent 3-month observation. The patient was treated with GM-CSF inhalation of high-dose administration (sargramostim, 125 μg twice daily on Days 1-8, and none on Days 9-14) for six 2-week cycles and consequent low dose administration months (125 μg once daily on Days 1-4, none on Days 5-14) for six 2-week cycles, using a jet nebulizer (LC Plus; PARI GmbH, Starnberg, Germany) which generates particles of mean mass aerodynamic diameter of 3.97-5.25 μm at a flow rate of 3-6 L/min, according to the manufacturer's instructions (11) . The peripheral shadows on the chest radiograph and CT as well as bronchoscopic findings showed marked improvement (Fig. 1D, 2C, 3B) , and serum levels of SP-D and KL-6 decreased. Amorphous materials had markedly decreased in BALF (macrophages, 89%; lymphocytes, 10%; neutrophils, 1%). No recurrence was observed during 
TBLB (×200) shows that the amorphous material is PAS-positive (B). Arrows indicate PAS-positive materials.
(A)
the five years following treatment. However, the serum level of GM-CSF antibody was still elevated (19.5 μg/mL) five years after the end of the GM-CSF inhalation therapy.
Discussion
A typical CT finding of PAP is a "crazy-paving appearance," distributed centrally in both lungs. Instead, the present case showed bilateral GGOs localized in peripheral subpleural areas from the basal to the apical segments. Ten Japanese cases of PAP with subpleural infiltrates on CT findings have been reported in the Japanese and English literature. Most patients had no symptoms, and their condition did not worsen without treatment (Table 2) (9, 10, (12) (13) (14) (15) (16) (17) (18) (19) . Eight out of ten patients had never been a smoker.
The 10 cases yielded CT images of two types. One type showed solitary pulmonary nodule (20) , as in Cases 5 (a nodule of 30 mm in diameter), 8 (nodules, not referred), and 10 (a nodule of 40×20 mm). In these cases, lung cancer was suspected. Then they underwent surgical resection under video-assisted thoracoscopy. Cases 5, 8 and 10 were diagnosed pathologically as PAP. However, GM-CSF antibody was not measured in two of the cases. Case 8 demonstrated multiple nodular lesions, of which one lesion was diagnosed as bronchoalveolar carcinoma; the rest were pulmonary alveolar proteinosis. It is particularly interesting that Case 8 demonstrated positive GM-CSF antibody. The other was GGO distributed in the subpleural area, which the remaining seven cases showed. Six of the seven were female. GM-CSF antibody was measured in five of the seven cases: all five were positive. Case 4 worsened two years later, but the others remained stable.
In patients with PAP, infiltrates often disappear from the peripheral region to the central region (1). Mohri et al. (14) speculated that the GGOs might extend from the periphery to the central region and develop into air space consolidation as respiratory symptoms occur, suggesting that patients with peripheral GGOs might be exhibiting early stages of PAP. In this regard, the present case developed GGOs that extend from the peripheral to the central region and which disappeared from the central area toward the peripheral region. Recently, it has been demonstrated that GM-CSF administration by subcutaneous injection (21, 22) or inhalation (2, 4, 11) improved the respiratory function as well as CT findings of autoimmune PAP patients. Inhaled GM-CSF might first reach the mildly-impaired, proximal region in the lungs and improve the function of the macrophages present in those locations. The restored function of these alveolar macrophages may contribute to improving the clearance in the adjacent, distal regions. The present report describes exacerbation and improvement of peripheral infiltrates of a PAP patient in a series of CT, supporting the speculations 
Key: n.a., not available; AM, ambroxol hydrochloride described by Mohri et al. (14) . Although whole-lung lavage (WLL) has been the standard therapy for PAP, the recent perspective of the pathophysiology of PAP is leading us to innovative treatment options including GM-CSF administration, plasmapheresis and B-cell depletion. GM-CSF inhalation could be considered as an alternative in patients refractory to WLL, with a contraindication to general anesthesia during WLL, or under the effects of immunosuppressants, as in the present case. The treatment options will become more defined, as our knowledge in this field including CT patterns advances.
The present case worsened after steroid therapy. Cyclosporine, which was added on the expectation of improving organizing pneumonia refractory to 1-year steroid treatment (23), might also be associated with the worsening in chest radiographs during its administration. It is notable that Case 3 worsened as well after prednisolone therapy for autoimmune hemolytic anemia as well (17) . Careful consideration should be devoted to steroid administration in the treatment of autoimmune PAP because of its lack of efficacy and its associated risk. Reportedly, steroid therapy increases the production of phospholipids (24) and down-regulates monocyte function (25) . To prevent inappropriate application of immunosuppressants, it is important to consider PAP in the differential diagnosis of such peripheral opacities, which requires detailed characterization of HRCT findings and serum markers. In this regard, GM-CSF antibody might be helpful for diagnosis.
In conclusion, PAP should be considered in the differential diagnosis of peripheral subpleural opacities. Measurement of GM-CSF antibody might be a useful diagnostic option. GM-CSF inhalation therapy improved the peripheral opacities observed on CT images of PAP patients.
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